PrimeC

NeuroSense Advances PrimeC Toward Potential ALS Approval

TEL AVIV, Israel, Aug. 31, 2026 NeuroSense Therapeutics Ltd. announced an accelerated and capital-efficient development strategy for PrimeC, its...

By cGxPwire Editor
September 2, 2026

.Clinical

NeuroSense PrimeC Shows Positive Phase 2 Alzheimer’s Biomarker Data

CAMBRIDGE, Mass., June 25, 2026 NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 randomized, double-blind, placebo-controlled...

By cGxPwire Editor
June 27, 2026

Pharma

NeuroSense Reports Positive Phase 2b PrimeC ALS Results

Cambridge, Massachusetts, March 16, 2026 NeuroSense Therapeutics Ltd. announced the publication of results from its PARADIGM Phase 2b clinical...

By cGxPwire Editor
March 17, 2026

.Clinical Bio-Pharma

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...